Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ABBV-901

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by AbbVie

Phase 1 Most advanced trial

ABBV Developer

1 Registered trials

What is ABBV-901?

ABBV-901 is an antibody-drug conjugate composed of a monoclonal antibody targeting folate receptor alpha conjugated to a DNA topoisomerase I inhibitor payload. Upon binding to FRa on tumor cells and internalization, the cytotoxic payload is released to inhibit DNA topoisomerase I, leading to DNA replication inhibition, cell cycle arrest, and apoptosis. It is studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: folate receptor alpha (FOLR1)
Mechanism: Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways: DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07278336	Phase 1	Ovarian Cancer	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Other drugs acting on FOLR1

Opugotamig Olatansine Phase 2 Sofetabart Mipitecan Phase 3 Torvutatug Samrotecan Phase 1 ZW191 Phase 1

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind ABBV-901

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z